NO20003552L - Progesteron-agonistforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsen, samt en fremgangsmÕte for bestemmelse av tilstedeværelse av steroidreseptorer, ligand-steroidreseptorkomplekser og en fremgangsmÕte - Google Patents

Progesteron-agonistforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsen, samt en fremgangsmÕte for bestemmelse av tilstedeværelse av steroidreseptorer, ligand-steroidreseptorkomplekser og en fremgangsmÕte

Info

Publication number
NO20003552L
NO20003552L NO20003552A NO20003552A NO20003552L NO 20003552 L NO20003552 L NO 20003552L NO 20003552 A NO20003552 A NO 20003552A NO 20003552 A NO20003552 A NO 20003552A NO 20003552 L NO20003552 L NO 20003552L
Authority
NO
Norway
Prior art keywords
steroid
compounds
pharmaceutical compositions
ligand
compound
Prior art date
Application number
NO20003552A
Other languages
English (en)
Other versions
NO20003552D0 (no
NO313049B1 (no
Inventor
Todd Kevin Jones
James E Edwards
Christopher M Tegley
Sarah J West
Lin Zhi
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/464,360 external-priority patent/US5693646A/en
Publication of NO20003552L publication Critical patent/NO20003552L/no
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of NO20003552D0 publication Critical patent/NO20003552D0/no
Publication of NO313049B1 publication Critical patent/NO313049B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/18Ring systems of four or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Liquid Crystal (AREA)
  • Peptides Or Proteins (AREA)
NO20003552A 1994-12-22 2000-07-10 Progesteron-agonistforbindelser, farmasöytiske preparater inneholdende disse og anvendelsen av forbindelsen NO313049B1 (no)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US36352994A 1994-12-22 1994-12-22
US08/464,360 US5693646A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/465,556 US5696133A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/464,546 US5693647A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/463,231 US5688808A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/464,541 US5688810A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/465,429 US5696127A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/462,643 US5696130A (en) 1994-12-22 1995-06-05 Tricyclic steroid receptor modulator compounds and methods
PCT/US1995/016096 WO1996019458A2 (en) 1994-12-22 1995-12-13 Steroid receptor modulator compounds and methods

Publications (3)

Publication Number Publication Date
NO20003552L true NO20003552L (no) 1997-08-14
NO20003552D0 NO20003552D0 (no) 2000-07-10
NO313049B1 NO313049B1 (no) 2002-08-05

Family

ID=27575415

Family Applications (5)

Application Number Title Priority Date Filing Date
NO19972591A NO310617B1 (no) 1994-12-22 1997-06-06 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse, samt anvendelse avforbindelsene eller sammensetningene for fremstilling avmedikamenter
NO20003534A NO312162B1 (no) 1994-12-22 2000-07-07 Progesteronreseptor-modulatorforbindelser, farmasöytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
NO20003551A NO312098B1 (no) 1994-12-22 2000-07-10 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse samt anvendelse avforbindelsene
NO20003552A NO313049B1 (no) 1994-12-22 2000-07-10 Progesteron-agonistforbindelser, farmasöytiske preparater inneholdende disse og anvendelsen av forbindelsen
NO20003550A NO20003550D0 (no) 1994-12-22 2000-07-10 Farmasøytiske sammensetninger og anvendelse herav

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NO19972591A NO310617B1 (no) 1994-12-22 1997-06-06 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse, samt anvendelse avforbindelsene eller sammensetningene for fremstilling avmedikamenter
NO20003534A NO312162B1 (no) 1994-12-22 2000-07-07 Progesteronreseptor-modulatorforbindelser, farmasöytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
NO20003551A NO312098B1 (no) 1994-12-22 2000-07-10 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse samt anvendelse avforbindelsene

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20003550A NO20003550D0 (no) 1994-12-22 2000-07-10 Farmasøytiske sammensetninger og anvendelse herav

Country Status (17)

Country Link
EP (7) EP1041066A1 (no)
JP (2) JPH10510840A (no)
CN (2) CN1172917C (no)
AT (2) ATE269336T1 (no)
AU (1) AU717251B2 (no)
BR (1) BR9510486A (no)
CA (1) CA2208347A1 (no)
CZ (1) CZ176197A3 (no)
DE (2) DE69531998T2 (no)
DK (1) DK0800519T3 (no)
ES (1) ES2208699T3 (no)
HU (1) HUT78117A (no)
NO (5) NO310617B1 (no)
NZ (1) NZ300739A (no)
PT (1) PT800519E (no)
RU (1) RU2191774C2 (no)
WO (1) WO1996019458A2 (no)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
DE69709752T2 (de) * 1996-06-27 2002-07-18 Ligand Pharmaceuticals, Inc. Androgen rezeptor modulator verbindungen und verfahren
AUPO427196A0 (en) 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
AU5729098A (en) * 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US6291442B1 (en) 1998-02-03 2001-09-18 The General Hospital Corporation Pharmacological modulators of voltage-gated potassium ion channels
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
HUP0100460A3 (en) * 1998-02-13 2003-03-28 Ligand Pharmaceuticals Inc San Glucocorticoid-selective anti-inflammatory agents
US6001846A (en) * 1998-02-17 1999-12-14 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
US6093825A (en) * 1998-05-27 2000-07-25 American Home Products Methods for preparation of 1,2-dihydroquinolines
US6093826A (en) 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
CA2334545A1 (en) 1998-06-12 1999-12-16 Ligand Pharmaceuticals Incorporated Treatment of anti-estrogen resistant breast cancer using rxr modulators
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
SK15922001A3 (sk) * 1999-05-04 2002-09-10 American Home Products Corporation Deriváty cyklotiokarbamátu ako modulátory receptora pre progesterón
US6339098B1 (en) * 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
AU4501800A (en) * 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
TR200103286T2 (tr) * 1999-05-04 2002-07-22 American Home Products Corporation Projesteron reseptörü modülatörleri olarak siklokarbamat türevleri
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
WO2000066560A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
CN1391576A (zh) 1999-08-27 2003-01-15 利甘德药品公司 雄激素受体调节剂化合物及方法
JP2003508397A (ja) 1999-08-27 2003-03-04 リガンド・ファーマシューティカルズ・インコーポレイテッド アンドロゲンレセプターモジュレーターとしての8−置換−6−トリフルオロメチル−9−ピリド[3,2−g]キノリン化合物
PT1229906E (pt) * 1999-08-31 2008-01-18 Bayer Schering Pharma Ag Mesoprogestinas para o tratamento e prevenção de distúrbios ginecológicos hormonodependentes benignos
PE20010647A1 (es) 1999-09-14 2001-06-23 Lilly Co Eli Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado
WO2001027086A1 (en) 1999-10-14 2001-04-19 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2001288213B2 (en) 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
JP2004515462A (ja) * 2000-06-28 2004-05-27 ブリストル−マイヤーズ スクイブ カンパニー 核ホルモン・レセプタ機能のモジュレーターとしての縮合環式化合物
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
EP1313700B1 (en) * 2000-08-23 2005-11-09 Akzo Nobel N.V. 10-aryl-11h-benzo[b]fluorene derivatives and analogs as estrogenic compounds
EP1325914A4 (en) * 2000-09-14 2004-11-17 Kaken Pharma Co Ltd TETRAHYDROQUINOLINE COMPOUNDS
SK4982003A3 (en) * 2000-09-19 2004-05-04 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
WO2003002548A1 (en) * 2001-06-29 2003-01-09 Abbott Laboratories A process for the preparation of chiral glucocorticoid receptor agents
US6608216B2 (en) 2001-06-29 2003-08-19 Abbott Laboratories Process for the preparation of chiral glucocorticoid receptor agents
HRP20031080A2 (en) * 2001-07-02 2004-04-30 Akzo Nobel Nv Tetrahydroquinoline derivatives
JP2003073374A (ja) * 2001-08-31 2003-03-12 Kaken Pharmaceut Co Ltd 2環性芳香族アミン誘導体
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
ES2310622T3 (es) 2001-12-19 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas.
ES2276038T3 (es) 2002-01-14 2007-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos.
TW200304371A (en) 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
ES2528764T3 (es) 2002-02-28 2015-02-12 University Of Tennessee Research Foundation Moduladores selectivos multisustituidos del receptor de andrógeno y métodos de uso de los mismos
WO2003078394A1 (en) 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
AU2003230700A1 (en) 2002-03-26 2003-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PL373043A1 (en) 2002-03-26 2005-08-08 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CN1315836C (zh) * 2002-04-26 2007-05-16 奥索-麦克尼尔药品公司 用作雄激素受体调节剂的2-(喹诺酮基)-稠合杂环
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1532113B1 (en) 2002-08-21 2008-08-06 Boehringer Ingelheim Pharmaceuticals Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP2006506445A (ja) 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
EP1558618A1 (en) * 2002-10-11 2005-08-03 Ligand Pharmaceuticals, Inc. 5-(1 ,1 -CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO- 5H /-CHROMENO[3,4-f ] QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
WO2004033460A1 (en) 2002-10-11 2004-04-22 Ligand Pharmaceuticals Incorporated 5-cycloalkenyl 5h-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
RU2005124558A (ru) 2003-01-03 2006-04-10 Берингер Ингельхайм Фармасьютиклз, Инк. (Us) Производные 1-пропанола и 1-пропиламина и их применение в качестве глюкокортикоидных лигандов
HRP20050859A2 (en) * 2003-03-28 2006-02-28 Pfizer Products Inc. 1,2,4-suptituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
AU2004266160A1 (en) 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7507843B2 (en) 2003-10-16 2009-03-24 Boehringer Ingelheim Pharmaceuticals, Inc. Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
WO2006029146A2 (en) 2004-09-07 2006-03-16 Wyeth 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS
US7635711B2 (en) 2004-12-27 2009-12-22 Boehringer-Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
BRPI0609191B8 (pt) 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
TWI375676B (en) * 2005-08-29 2012-11-01 Msd Oss Bv Non-steroidal glucocorticoid receptor modulators
JP4825636B2 (ja) * 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規1,2−ジヒドロキノリン誘導体
CN101263119B (zh) 2005-09-14 2014-04-09 参天制药株式会社 具有糖皮质激素受体结合活性的1,2-二氢喹啉衍生物
US20090203725A1 (en) * 2005-12-21 2009-08-13 Cornelis Arjan Van Oeveren Androgen Receptor Modulator Compounds and Methods
NZ570533A (en) * 2006-03-03 2011-02-25 Orion Corp Compounds useful as Selective androgen receptor modulators (SARM), in particular (2S)-3-(4-cyano-3-fluorophenoxy)-N-(4-cyano-3-methylphenyl)-2-hydroxy-2-methylpropionamide useful in hormonal therapy
PL2085388T3 (pl) 2006-11-14 2013-01-31 Santen Pharmaceutical Co Ltd Nowa pochodna 1,2-dihydrochinoliny, zawierająca jako podstawniki podstawioną grupę fenyloamino-niższą alkilową oraz wprowadzoną przez ester grupę fenylową
MX2009005264A (es) 2006-12-06 2009-05-28 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
TWI410422B (zh) 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
WO2008111632A1 (ja) * 2007-03-13 2008-09-18 Santen Pharmaceutical Co., Ltd. 2,2,4-トリメチル-6-フェニル-1,2-ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2009103007A2 (en) * 2008-02-13 2009-08-20 Ligand Pharmaceuticals Incorporated Steroid hormone receptor modulator compounds and methods
BRPI0912171B8 (pt) * 2008-05-12 2021-05-25 Ayumi Pharmaceutical Corp composto ativador de receptor de glicocorticoide, e, composição
EP2130831A1 (en) 2008-06-06 2009-12-09 InterMed Discovery GmbH CDC25 inhibitors
CA2726449A1 (en) 2008-06-06 2009-12-10 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CN102239149B (zh) 2008-10-06 2015-05-13 约翰·霍普金斯大学 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
CN103613538B (zh) * 2013-11-22 2015-05-20 山东斯递尔化工科技有限公司 一种2,2,4-三甲基-1,2-二氢化喹啉聚合体的催化合成工艺
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
EP3265127B1 (en) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
CA2978960C (en) 2015-03-30 2023-05-02 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CA2994422A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
WO2017127448A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
CN106397317B (zh) * 2016-09-26 2019-03-22 天津师范大学 1,2,3,4-四氢喹啉化合物及其合成方法与应用
FI3600282T3 (fi) 2017-03-31 2025-11-07 Corcept Therapeutics Inc Glukokortikoidireseptorien modulaattoreita kohdunkaulan syövän hoitoon
JP7670462B2 (ja) 2017-06-20 2025-04-30 コーセプト セラピューティクス, インコーポレイテッド 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
CN107805248A (zh) * 2017-11-01 2018-03-16 长春海谱润斯科技有限公司 一种含有苯并咪唑结构的衍生物及其制备方法和有机电致发光器件
CN111499607B (zh) * 2019-01-30 2022-04-19 哈尔滨工业大学(深圳) 一种六元芳基内酯或六元芳基内酰胺化合物的制备方法
CN114096522A (zh) 2019-04-19 2022-02-25 利亘制药公司 化合物的晶型和制备化合物的晶型的方法
EP4263807A2 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
CN119409635B (zh) * 2024-11-04 2026-01-09 河南师范大学 具有抗癌活性的氟代甲基取代茚并[1,2-b]吡啶类化合物及其合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635941A (en) * 1969-04-01 1972-01-18 Eastman Kodak Co Disperse mono azo dyes containing an acylamidotetrahydroquinoline group
GB1379387A (en) * 1970-12-11 1975-01-02 Agfa Gevaert Photoconductive recording materials
US3907507A (en) * 1971-04-26 1975-09-23 Heliodoro Monroy Rivera Novel apparatus for the obtention of substituted 1,2-dihydroquinolines
GB8619902D0 (en) * 1986-08-15 1986-09-24 Pfizer Ltd Quinolone cardiac stimulants
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
GB8709448D0 (en) * 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
ES2245660T3 (es) * 1990-11-30 2006-01-16 Otsuka Pharmaceutical Co., Ltd. Derivados de azol y su utilizacion como inhibidores de los radicales superoxidos.
JPH04316557A (ja) * 1991-04-16 1992-11-06 Kyorin Pharmaceut Co Ltd 6−アリール環状アントラニル酸誘導体
RU2032685C1 (ru) * 1991-12-16 1995-04-10 Центр по химии лекарственных средств Производные пиридо (3,2-а)карбазола, обладающие кардиотонической активностью
JP2686887B2 (ja) * 1992-08-11 1997-12-08 キッセイ薬品工業株式会社 ピペリジノ−3,4−ジヒドロカルボスチリル誘導体

Also Published As

Publication number Publication date
CZ176197A3 (cs) 1998-09-16
WO1996019458A2 (en) 1996-06-27
DE69531998D1 (de) 2003-11-27
ES2208699T3 (es) 2004-06-16
WO1996019458A3 (en) 1996-12-12
NO20003551L (no) 1997-08-14
NO20003552D0 (no) 2000-07-10
NO312098B1 (no) 2002-03-18
EP1382597A2 (en) 2004-01-21
CN1626534A (zh) 2005-06-15
ATE252560T1 (de) 2003-11-15
CN1172917C (zh) 2004-10-27
NO20003551D0 (no) 2000-07-10
EP1043326A1 (en) 2000-10-11
AU717251B2 (en) 2000-03-23
DE69531998T2 (de) 2004-07-22
CA2208347A1 (en) 1996-06-27
NO20003534D0 (no) 2000-07-07
DK0800519T3 (da) 2004-03-01
NO310617B1 (no) 2001-07-30
NO312162B1 (no) 2002-04-02
ATE269336T1 (de) 2004-07-15
CN1175247A (zh) 1998-03-04
NO972591D0 (no) 1997-06-06
NO20003550L (no) 1997-08-14
DE69533180T2 (de) 2005-07-14
NO313049B1 (no) 2002-08-05
NO20003550D0 (no) 2000-07-10
EP1043325A1 (en) 2000-10-11
EP0800519A1 (en) 1997-10-15
DE69533180D1 (de) 2004-07-22
NO20003534L (no) 1997-08-14
EP1043325B1 (en) 2004-06-16
EP0800519B1 (en) 2003-10-22
NZ300739A (en) 2000-05-26
EP1041066A1 (en) 2000-10-04
JP2007217418A (ja) 2007-08-30
JPH10510840A (ja) 1998-10-20
PT800519E (pt) 2004-03-31
EP1041071A1 (en) 2000-10-04
RU2191774C2 (ru) 2002-10-27
EP1043315A1 (en) 2000-10-11
AU4597796A (en) 1996-07-10
EP1382597A3 (en) 2004-04-07
HUT78117A (hu) 1999-11-29
NO972591L (no) 1997-08-14
BR9510486A (pt) 1998-06-02

Similar Documents

Publication Publication Date Title
NO20003552D0 (no) Progesteron-agonistforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsen, samt en fremgangsmÕte for bestemmelse av tilstedeværelse av steroidreseptorer, ligand-steroidreseptorkomplekser og en fremgangsmÕte
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
DE69709752D1 (de) Androgen rezeptor modulator verbindungen und verfahren
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
DE69821132D1 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
ATE245993T1 (de) Allosterische modulatoren des nmda-rezeptors
NO981501L (no) Dimer-selektive RXR modulatorer og fremgangsmÕte for anvendelse derav
IL128003A (en) MULTISPECIFIC BINDING MOLECULES COMPRISING A BINDING DETERMINANT WHICH BINDS AN FCalpha RECEPTOR
IL180603A (en) 3,4-Dihydro-1 H- Naphthalanones which are glucocorticoid receptor modulators
DK0807111T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstillingen heraf samt farmaceutiske sammensætninger indeholdende disse
ATE449076T1 (de) Imidazolderivate als histamin-h3-modulatoren
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
NZ504471A (en) An Ox receptor distinct from known alpha 2-adenoreceptors and imidazoline receptors (I1 and I2) with an affinity for compounds of the oxazoline class
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
NZ515382A (en) OX2 receptor homologs
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
CA2259031A1 (en) Androgen receptor modulator compounds and methods